Regulus Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
04 Fevereiro 2025 - 10:00AM
PR Newswire (US)
SAN
DIEGO, Feb. 4, 2025 /PRNewswire/ -- Regulus
Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company
focused on the discovery and development of innovative medicines
targeting microRNAs (the "Company" or "Regulus"), today announced
that members of the management team will participate in a fireside
chat at the Oppenheimer 35th Annual Healthcare Life Sciences
Conference on Tuesday, February
11th at 2:40 p.m.
ET.
The live event and replay of the presentation will be available
under "Events and Presentations" through the investor relations
section of the Company's website at https://ir.regulusrx.com/events
and archived for 90 days following the presentation date.
About Regulus
Regulus Therapeutics Inc. (Nasdaq: RGLS)
is a biopharmaceutical company focused on the discovery and
development of innovative medicines targeting microRNAs. Regulus
has leveraged its oligonucleotide drug discovery and development
expertise to develop a pipeline complemented by a rich intellectual
property estate in the microRNA field. Regulus maintains its
corporate headquarters in San Diego,
CA.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/regulus-therapeutics-to-present-at-the-oppenheimer-35th-annual-healthcare-life-sciences-conference-302366886.html
SOURCE Regulus Therapeutics Inc.
Copyright 2025 PR Newswire
Regulus Therapeutics (NASDAQ:RGLS)
Gráfico Histórico do Ativo
De Jan 2025 até Fev 2025
Regulus Therapeutics (NASDAQ:RGLS)
Gráfico Histórico do Ativo
De Fev 2024 até Fev 2025